Title 21, Food and DrugsRelease 119-110

§1714 Awards for Demonstration Programs by Local Partnerships to Coerce Abstinence in Chronic Hard-drug Users Under Community Supervision Through the Use of Drug Testing and Sanctions

Title 21 › CHAPTER 22 — NATIONAL DRUG CONTROL POLICY › § 1714

Last updated Sep 22, 2026|Official source

Summary

The Director must give competitive grants to pay for trial programs run by local partnerships. These programs must try to cut illegal drug use by chronic hard‑drug users who live in the community and are under criminal justice supervision. Grant money must support the partners, build a drug‑testing program with stepped penalties, and help people with rehab like job training, drug treatment, or other services. An eligible partnership must include two or more agencies or groups (for example state, local, tribal, federal, or community organizations), a qualified researcher, a plan to test people at least twice a week and quickly use clear graduated sanctions for non‑compliance, a strategy for different levels of drug use and criminal history, a plan to link data systems for real‑time tracking, and a way to measure progress by tracking who skips tests or tests positive. The Director must send a report on best practices by June 1, 2009 and a final report on the programs by June 1, 2010. Up to $4,900,000 is authorized for each of fiscal years 2007 through 2009.

Full Legal Text

Title 21, §1714

Food and Drugs, Source: USLM XML via OLRC

(a)Awards required
The Director shall make competitive awards to fund demonstration programs by eligible partnerships for the purpose of reducing the use of illicit drugs by chronic hard-drug users living in the community while under the supervision of the criminal justice system.
(b)Use of award amounts
Award amounts received under this section shall be used—
(1)to support the efforts of the agencies, organizations, and researchers included in the eligible partnership;
(2)to develop and field a drug testing and graduated sanctions program for chronic hard-drug users living in the community under criminal justice supervision; and
(3)to assist individuals described in subsection (a) by strengthening rehabilitation efforts through such means as job training, drug treatment, or other services.
(c)Eligible partnership defined
In this section, the term “eligible partnership” means a working group whose application to the Director— (1)
(2)includes a qualified researcher;
(3)includes a plan for using judicial or other criminal justice authority to administer drug tests to individuals described in subsection (a) at least twice a week, and to swiftly and certainly impose a known set of graduated sanctions for non-compliance with community-release provisions relating to drug abstinence (whether imposed as a pre-trial, probation, or parole condition or otherwise);
(4)includes a strategy for responding to a range of substance use and abuse problems and a range of criminal histories;
(5)includes a plan for integrating data infrastructure among the agencies and organizations included in the eligible partnership to enable seamless, real-time tracking of individuals described in subsection (a);
(6)includes a plan to monitor and measure the progress toward reducing the percentage of the population of individuals described in subsection (a) who, upon being summoned for a drug test, either fail to show up or who test positive for drugs.
(d)Reports to Congress
(1)Interim report
Not later than June 1, 2009, the Director shall submit to Congress a report that identifies the best practices in reducing the use of illicit drugs by chronic hard-drug users, including the best practices identified through the activities funded under this section.
(2)Final report
Not later than June 1, 2010, the Director shall submit to Congress a report on the demonstration programs funded under this section, including on the matters specified in paragraph (1).
(e)Authorization of appropriations
There is authorized to be appropriated to carry out this section $4,900,000 for each of fiscal years 2007 through 2009.

Legislative History

Notes & Related Subsidiaries

Editorial Notes

Amendments

2018—Pub. L. 115–271, § 8202(b)(2), repealed Pub. L. 105–277, § 715. See 1998 Amendment note below. Pub. L. 115–271, § 8202(a), revived and restored this section as in effect on Sept. 29, 2003, and as amended by Pub. L. 109–469 and Pub. L. 112–166. See Reauthorization of the Office of National Drug Control Policy note set out under section 1701 of this title. 2006—Pub. L. 109–469 amended Pub. L. 105–277, § 715, which provided for the repeal of this section. See 1998 Amendment note below. 1998—Pub. L. 105–277, § 715, as amended by Pub. L. 109–469, § 602, which provided for the repeal of this section effective Sept. 30, 2010, was repealed by Pub. L. 115–271, § 8202(b)(2). See former section 1712 of this title.

Reference

Citations & Metadata

Citation

21 U.S.C. § 1714

Title 21, Food and Drugs

Last Updated

Sep 22, 2026

Release point: 119-110